This program is intended for American College of Chest Physicians attendees only. Activity Chair Fernando J. Martinez, MD, MSChief, Division of Pulmonary and Critical Care MedicineWeill Cornell MedicineNew York, NY Faculty Kevin R. Flaherty, MD, MSProfessor of MedicineDivision of Pulmonary/Critical Care MedicineDirector, Michigan Medicine Interstitial Lung Disease ClinicUniversity of MichiganAnn Arbor, MI Lisa H. Lancaster, MDAssociate ProfessorDivision of Allergy, Pulmonary, and Critical Care MedicineDirector, Vanderbilt Interstitial Lung Disease ProgramVanderbilt University Medical CenterNashville, TN Overview Interstitial lung disease (ILD) describes a group of over 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, occupational hazards, or an underlying medical condition such as connective tissue disease (CTD). Patients with systemic sclerosis, rheumatoid arthritis, or poly-/dermatomyositis, have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive fibrosing phenotype (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit those suffering from PF-ILD. In this continuing medical education activity featuring Wheel of Knowledge, expert physicians will discuss the latest information regarding the diagnosis and treatment of PF-ILD. Agenda 11:45 AMRegistration and Lunch 12:00 PM Introduction and PretestFernando J. Martinez, MD, MS 12:05 PM Improving Outcomes for Patients With PF-ILD – Toward Timely and Accurate DiagnosisLisa H. Lancaster, MD 12:20 PM New Applications for Current IPF Therapies: What Does It Mean for Practice?Kevin R. Flaherty, MD, MS 12:40 PM Wheel of PF-ILD KnowledgeWith your host, Fernando J. Martinez, MD, MS 12:55 PMQuestion and Answer 1:00 PMConclusion Learning Objectives Upon successful completion of this activity, participants should be better able to: Apply the latest evidence and guidelines to identity patients with PF-ILD in a timely and accurate manner. Assess the latest clinical evidence in the management of PF-ILD, including the significance of both pulmonary and non-pulmonary endpoints. Identify patients with worsening PF-ILD despite receiving current standard of care who may benefit from emerging treatment options. Review the importance of a multidisciplinary approach for the improved diagnosis and treatment of patients with PF-ILD. Target Audience The intended audience for this activity is pulmonologists, rheumatologists and other health care professionals involved in the management of patients with PF-ILD. This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. This symposium is not sponsored, endorsed, or accredited by the American College of Chest Physicians. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience. Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee. MIPS Qualifying Activity:Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.